Skip to main content
Top
Published in: Ophthalmology and Therapy 6/2024

Open Access 25-04-2024 | Presbyopia | ORIGINAL RESEARCH

Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study

Authors: Brian M. Shafer, Selina R. McGee, Cristos Ifantides, Blake K. Williamson, Shane Kannarr, Julie Whyte, Zuoyi Zhang, Travis Yanke, Scott Schachter

Published in: Ophthalmology and Therapy | Issue 6/2024

Login to get access

Abstract

Introduction

The phase 3, randomized, vehicle-controlled, 14-day VIRGO study evaluated the efficacy and safety of twice-daily dosing of pilocarpine hydrochloride ophthalmic solution 1.25% (Pilo) in presbyopia. On VIRGO exit, a companion study was conducted to assess the patient experience with presbyopia and satisfaction with Pilo.

Methods

Recruited individuals completed the Presbyopia Patient Satisfaction Questionnaire (PPSQ) plus a three-part exit survey, or a live interview. The PPSQ evaluated respondents’ experience with Pilo. Survey parts 1 and 2 evaluated experience managing presbyopia before and during VIRGO, respectively; part 3 assessed future possibilities of using Pilo in real-world situations. The interview further informed the interviewees’ experience with presbyopia and Pilo. The primary endpoint was responders (%) in each rating category of the PPSQ items 1–7; the secondary endpoints were summary of categorical (survey) and qualitative (interviews) responses.

Results

The PPSQ and survey included 62 participants who received Pilo (N = 28) or vehicle (N = 34) in VIRGO; the interview included ten participants (Pilo, N = 4; vehicle, N = 6). Per the PPSQ, 64.3% of Pilo users reported vision improvement, including 17.9% with complete improvement; ≥ 46.4% were satisfied/very satisfied with their ability to perform daily activities, see up close unaided, and read in dim light. Among vehicle users, these percentages were 35.3%, 0%, and ≤ 23.5%, respectively. In both subgroups, ≥ 67.9% were interested in using Pilo or Pilo and eyeglasses/contact lenses in the future. Per the interview, vehicle users (n = 6/6) found the eyedrop easy to use but none experienced meaningful near-vision improvements, stopped using other correction method(s) part of the day, were satisfied with the eyedrop, preferred it over their previous correction method(s), or would continue using it if prescribed. Conversely, 75% (n = 3/4) of Pilo users responded positively to each of these six criteria.

Conclusions

Findings validate the VIRGO results and improve our understanding of the patient experience, demonstrating improved vision and satisfaction with Pilo (vs. vehicle) when performing daily activities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Waring GO IV, Chang DH, Rocha KM, Gouvea L, Penatti R. Correlation of intraoperative optical coherence tomography of crystalline lens diameter, thickness, and volume with biometry and age. Am J Ophthalmol. 2021;225:147–56.CrossRefPubMed Waring GO IV, Chang DH, Rocha KM, Gouvea L, Penatti R. Correlation of intraoperative optical coherence tomography of crystalline lens diameter, thickness, and volume with biometry and age. Am J Ophthalmol. 2021;225:147–56.CrossRefPubMed
2.
go back to reference Mercer RN, Milliken CM, Waring GO IV, Rocha K. Future trends in presbyopia correction. J Refract Surg. 2021;37:S28–34.CrossRefPubMed Mercer RN, Milliken CM, Waring GO IV, Rocha K. Future trends in presbyopia correction. J Refract Surg. 2021;37:S28–34.CrossRefPubMed
3.
go back to reference American Optometric Association. Optometric clinical practice guideline—care of the patient with presbyopia. St. Louis: American Optometric Association; 2011. American Optometric Association. Optometric clinical practice guideline—care of the patient with presbyopia. St. Louis: American Optometric Association; 2011.
4.
go back to reference GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e130–43. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e130–43.
6.
go back to reference Stokes J, Shirneshan E, Graham CA, Paulich M, Johnson N. Exploring the experience of living with and managing presbyopia. Optom Vis Sci. 2022;99:635–44.CrossRefPubMed Stokes J, Shirneshan E, Graham CA, Paulich M, Johnson N. Exploring the experience of living with and managing presbyopia. Optom Vis Sci. 2022;99:635–44.CrossRefPubMed
7.
go back to reference Berdahl J, Bala C, Dhariwal M, Lemp-Hull J, Thakker D, Jawla S. Patient and economic burden of presbyopia: a systematic literature review. Clin Ophthalmol. 2020;14:3439–50.CrossRefPubMedPubMedCentral Berdahl J, Bala C, Dhariwal M, Lemp-Hull J, Thakker D, Jawla S. Patient and economic burden of presbyopia: a systematic literature review. Clin Ophthalmol. 2020;14:3439–50.CrossRefPubMedPubMedCentral
8.
go back to reference Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. BMJ Open Ophthalmol. 2023;8(1):e001122 Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. BMJ Open Ophthalmol. 2023;8(1):e001122
9.
11.
go back to reference Waring GO IV, Price FW Jr, Wirta D, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140:363–71.CrossRefPubMedPubMedCentral Waring GO IV, Price FW Jr, Wirta D, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140:363–71.CrossRefPubMedPubMedCentral
12.
go back to reference Kannarr S, El-Harazi SM, Moshirfar M, et al. Safety and efficacy of twice-daily pilocarpine HCl In presbyopia: the VIRGO phase 3, randomized, double-masked, controlled study. Am J Ophthalmol. 2023;253:189–200.CrossRefPubMed Kannarr S, El-Harazi SM, Moshirfar M, et al. Safety and efficacy of twice-daily pilocarpine HCl In presbyopia: the VIRGO phase 3, randomized, double-masked, controlled study. Am J Ophthalmol. 2023;253:189–200.CrossRefPubMed
14.
go back to reference Barnett M, McGee S, Pack W, Yuan J, Shirneshan E, Campbell J. No impact of headache or visual impairment adverse events following AGN-190584 observed on patient-reported outcomes. Denver: Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, 1–4 May 2022. Barnett M, McGee S, Pack W, Yuan J, Shirneshan E, Campbell J. No impact of headache or visual impairment adverse events following AGN-190584 observed on patient-reported outcomes. Denver: Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, 1–4 May 2022.
15.
go back to reference Evans DG, Coon C, Nichols KK, Shirneshan E, Campbell J. Interpreting clinically meaningful near vision improvement in presbyopia with AGN-190584 in the GEMINI 1 phase 3 trial. Boston: American Academy of Optometry (AAOpt) Academy 2021 Annual Meeting, 3–6 November 2021. Evans DG, Coon C, Nichols KK, Shirneshan E, Campbell J. Interpreting clinically meaningful near vision improvement in presbyopia with AGN-190584 in the GEMINI 1 phase 3 trial. Boston: American Academy of Optometry (AAOpt) Academy 2021 Annual Meeting, 3–6 November 2021.
16.
go back to reference Wirta D, Christie W, Tauber J, Shirneshan E, Lee S, Campbell J. Assessing presbyopia impacts and coping behaviors with de novo PRO instruments in a phase 3 study of AGN-190584 (Pilocarpine 1.25%). Las Vegas: 2021 American Society of Cataract and Refractive Surgery Annual Meeting, 23–27 July 2021. Wirta D, Christie W, Tauber J, Shirneshan E, Lee S, Campbell J. Assessing presbyopia impacts and coping behaviors with de novo PRO instruments in a phase 3 study of AGN-190584 (Pilocarpine 1.25%). Las Vegas: 2021 American Society of Cataract and Refractive Surgery Annual Meeting, 23–27 July 2021.
17.
go back to reference McCabe CM, Wirta D, Price FWJ, Lee S, Shirneshan E, Campbell JT. Patient-reported outcomes in pooled phase 3 studies of AGN-190584 (Pilocarpine 1.25%) for presbyopia. New Orleans: American Academy of Ophthalmology 2021 Annual Meeting, 12–13 November 2021. McCabe CM, Wirta D, Price FWJ, Lee S, Shirneshan E, Campbell JT. Patient-reported outcomes in pooled phase 3 studies of AGN-190584 (Pilocarpine 1.25%) for presbyopia. New Orleans: American Academy of Ophthalmology 2021 Annual Meeting, 12–13 November 2021.
18.
go back to reference Charmaz K. Grounded theory. In: Smith J, Harré R, Van Langenhove L, editors. Rethinking methods in psychology. London: Sage Publications; 1995. p. 27–49.CrossRef Charmaz K. Grounded theory. In: Smith J, Harré R, Van Langenhove L, editors. Rethinking methods in psychology. London: Sage Publications; 1995. p. 27–49.CrossRef
19.
20.
go back to reference Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding in-depth semistructured interviews: problems of unitization and intercoder reliability and agreement. Sociol Methods Res. 2013;42:294–320.CrossRef Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding in-depth semistructured interviews: problems of unitization and intercoder reliability and agreement. Sociol Methods Res. 2013;42:294–320.CrossRef
21.
go back to reference Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27:591–608.CrossRefPubMed Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27:591–608.CrossRefPubMed
22.
go back to reference Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18:59–82.CrossRef Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18:59–82.CrossRef
23.
go back to reference Goertz AD, Stewart WC, Burns WR, Stewart JA, Nelson LA. Review of the impact of presbyopia on quality of life in the developing and developed world. Acta Ophthalmol. 2014;92:497–500.CrossRefPubMed Goertz AD, Stewart WC, Burns WR, Stewart JA, Nelson LA. Review of the impact of presbyopia on quality of life in the developing and developed world. Acta Ophthalmol. 2014;92:497–500.CrossRefPubMed
24.
go back to reference Luo BP, Brown GC, Luo SC, Brown MM. The quality of life associated with presbyopia. Am J Ophthalmol. 2008;145:618–22.CrossRefPubMed Luo BP, Brown GC, Luo SC, Brown MM. The quality of life associated with presbyopia. Am J Ophthalmol. 2008;145:618–22.CrossRefPubMed
25.
go back to reference McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. 2003;121:1577–81.CrossRefPubMed McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. 2003;121:1577–81.CrossRefPubMed
27.
go back to reference Brujic M, Kruger P, Todd J, et al. Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals. BMC Ophthalmol. 2022;22:204.CrossRefPubMedPubMedCentral Brujic M, Kruger P, Todd J, et al. Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals. BMC Ophthalmol. 2022;22:204.CrossRefPubMedPubMedCentral
Metadata
Title
Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study
Authors
Brian M. Shafer
Selina R. McGee
Cristos Ifantides
Blake K. Williamson
Shane Kannarr
Julie Whyte
Zuoyi Zhang
Travis Yanke
Scott Schachter
Publication date
25-04-2024
Publisher
Springer Healthcare
Keyword
Presbyopia
Published in
Ophthalmology and Therapy / Issue 6/2024
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-024-00935-w

Other articles of this Issue 6/2024

Ophthalmology and Therapy 6/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare